Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Autor: Thompson PA; Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA., Lévy V; URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France., Tam CS; Department of Haematology and Medical Oncology, The Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia., Al Nawakil C; URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France., Goudot FX; Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France., Quinquenel A; Service Hématologie Clinique, Hopital Robert Debré, CHU Reims, Reims, France., Ysebaert L; Service d'Hématologie, IUCT-Oncopole, Toulouse, France., Michallet AS; Centre Léon Bérard, Lyon, France., Dilhuydy MS; Service d'hématologie, Hopital Haut Leveque, Pessac, France., Van Den Neste E; Department of Haematology, Cliniques universitaires UCL Saint-Luc, Brussels, Belgium., Dupuis J; Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France., Keating MJ; Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA., Meune C; Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France., Cymbalista F; Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny, France. florence.cymbalista@avc.aphp.fr.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2016 Nov; Vol. 175 (3), pp. 462-466. Date of Electronic Publication: 2016 Sep 09.
DOI: 10.1111/bjh.14324
Abstrakt: Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.
(© 2016 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: